## MEDICARE PHYSICIAN FEE SCHEDULE RATES – NATIONAL MEDICARE PAYMENT AMOUNT

### CPT | DESCRIPTION (NASAL PROCEDURES) | NON-FACILITY
--- | --- | ---
30110 | Excision, nasal polyp(s), simple | $246.13
30560 | Lysis of adhesions | $300.99
30801 | Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (e.g., electrocautery, radiofrequency ablation, or tissue reduction); superficial | $223.03
30802 | Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (e.g., electrocautery, radiofrequency ablation, or tissue reduction); intramural (i.e. submucosal) | $283.66
31231 | Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | $197.77
31237 | Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure) | $260.21
31253 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including frontal sinus exploration, with removal of tissue from frontal sinus, when performed | $519.69
31254 | Nasal/sinus endoscopy, surgical with ethmoidectomy; partial (anterior) | $432.71
31255 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior) | $335.99
31257 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy | $462.67
31259 | Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy, with removal of tissue from the sphenoid sinus | $489.74

### CPT | EVALUATION and MANAGEMENT | NON-FACILITY
--- | --- | ---
99211 | Office/outpatient visit, established patient, minimal problem(s), short duration | $23.46
99212 | Office/outpatient visit established patient | $46.19
99213 | Office/outpatient visit established patient | $76.15
99214 | Office/outpatient visit established patient | $110.43
99215 | Office/outpatient visit, established patient, complex problem(s), lengthy, comprehensive, detailed examination | $148.33

*Rates listed reflect policies adopted in the CY 2020 Medicare Physician Fee Schedule Final Rule published November 1, 2019. All rates shown are national averages and do not include adjustments for geographic cost variations or the 2% reduction in Medicare’s share of the payment due to sequestration under the Budget Control Act of 2011.*
**INDICATION**

SINUVA Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.

**IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS**

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA Sinus Implant.

**WARNINGS AND PRECAUTIONS**

Local Effects: Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

**Ocular Effects:** Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts closely.

**Hypersensitivity Reactions:** Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.

**Immunosuppression:** Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

**Hypercorticism and Adrenal Suppression:** If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

**ADVERSE REACTIONS**

The most common adverse reactions observed (> 1% of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.

**POSTMARKETING EXPERIENCE**

The following adverse reactions have been identified during post-approval use of the SINUVA sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.

Rx only. Please see Full Prescribing Information for SINUVA at SINUVA.com/hcp

---

1. Follow-up visits represent the same schedule as RESOLVE II study
2. General procedures and associated CPTs physicians perform during in-office visits